varlitinib + docetaxel

**Varlitinib + docetaxel** is an experimental combination therapy under clinical investigation for solid tumors and breast cancer. - **Varlitinib** (ARRY-334543) is a potent, orally active, reversible, small molecule tyrosine kinase inhibitor that selectively targets both ErbB-2 (HER2/neu) and EGFR (ErbB-1). It acts as an ATP-competitive inhibitor and demonstrates nanomolar potency, aiming to inhibit tumor cell growth and survival pathways. Varlitinib also reverses multidrug resistance mediated by certain ABC transporters (notably ABCG2), potentially enhancing chemotherapeutic efficacy[1][4][5][8]. - **Docetaxel** is a well-established antimicrotubule chemotherapeutic agent, classified as a taxane, which inhibits cell division by stabilizing microtubules and is commonly used in various solid tumors (notably breast, lung, prostate cancers). The rationale for combining varlitinib with docetaxel is based on evidence for additive or synergistic anti-tumor effect, particularly in tumors overexpressing HER2 or EGFR, and to potentially overcome resistance mechanisms[5].

Other names

varlitinib + docetaxelARRY-334543 + docetaxel